Name:  ___                 Unit No:   ___
 
Admission Date:  ___              Discharge Date:   ___
 
Date of Birth:  ___             Sex:   M
 
Service: MEDICINE
 
Allergies: 
atorvastatin
 
Attending: ___.
 
Chief Complaint:
submandibular hematoma
 
Major Surgical or Invasive Procedure:
none
 
History of Present Illness:
___ h/o marfanoid features and MVR replacement ___ on 
warfarin p/w several days of increasing swelling at the base of 
his tongue. Last night he noticed a dark discoloration 
developing at the base of the tongue as well, prompting him to 
visit the ED. He endorses dysphagia and dysarthria ___ tongue 
swelling, but denies dyspnea or SOB. He does not recall any 
trauma or event that could have precipitated a bleed to the 
area. Pt denies sx of infectious process. On arrival to the ED, 
his INR was found to be supratherapeutic to 11.1. Pt states that 
he often has trouble maintaining his INR within therapeutic 
range of 2.5-3.5. CT neck demonstrates a 6mm hypodensity in the 
left submandibular area. We will admit to SICU for airway watch 
i.s.o supratherapeutic INR with likely submandibular bleed and 
acute airway swelling.

 
Past Medical History:
PAST PSYCHIATRIC HISTORY:
Diagnoses: depression, alcohol use disorder
Hospitalizations: none
Current treaters and treatment: none
Medication and ECT trials: hx of prozac
Self-injury:denies
Harm to others: denies

PMHx:
s/p MVR
nonobstructive CAD on cath ___ no h/o MI no interventions
 
Social History:
___
Family History:
Father w/ CAD (angina) at upper ___. Aunt and uncle with lung 
cancer (smokers). No other CAD, mother and brother healthy. 

FAMILY PSYCHIATRIC HISTORY:
Cousin committed suicide

 
Physical Exam:
ADMISSION PHYSICAL EXAM
========================

Vitals: 
___: Temperature: a) 97.8; b) 97.8
___: Heart Rate: a) 69; b) 69
___: BP: a) 132/81; b) 122/78 (Repeat right arm sitting); 
c)
132/81
___: O2 Saturation%: a) 99; b) 99

General: NAD, A&Ox3, well developed & nourished patient
Voice: normal with good projection and no evidence of dysphonia,
+ dysarthria
Respiratory Effort: unlabored without stridor or stertor
Eyes: Extraocular movements intact, pupils equally round and
reactive to light, no lid or conjunctival inflammation or
drainage
CN: V1-V3 intact to light touch, facial motion symmetric and
intact in all distributions, strong shoulder shrug, tongue
protrudes midline without fasciculation, able to range tongue
side to side
Face:  No gross lesions.  Sinuses not tender to palpation.
Ears:
AD: Auricle without tenderness to palpation, erythema, or
lesions. 
AS: Auricle without tenderness to palpation, erythema, or
lesions.  
Nose/Nasopharynx: By anterior rhinoscopy there is no pus or
polyps, mucosa is pink and moist, septum is minimally deviated,
turbinates are minimally edematous
Oral Cavity/Oropharynx: Mucous membranes are moist and pink,
tongue without lesions, floor of mouth ecchymotic and edematous
however soft to palpation, no trismus, no mucosal lesions,
salivary secretions are clear. Teeth in good condition.
Salivary:  Parotid glands normal, no tenderness, swelling or
masses.  Submandibular glands normal size and shape, no
tenderness, able to express saliva to bilateral ducts
TMJ: No tenderness
Neck: No masses, adenopathy or tenderness. Ptotic right
submandibular gland. Trachea midline. 

Fiberoptic exam
In the context of the patient's clinical presentation and the
need to visualize the regions in close proximity, the decision
was made to proceed with an endoscopic exam.  Accordingly, after
verbal consent, and use of endosheath, the fiberoptic scope was
passed to visualize the regions of concern.  The findings were:

Nasal cavity:  Turbinate mucosa pink, moist, minimally 
edematous;
no drainage, pus or polyps 
Nasopharynx:  Minimal residual adenoid tissue, no lesions or
masses
Oropharynx:  Symmetric soft palatal elevation, no mucosal
lesions, masses, or erythema, tongue base without lesions
Hypopharynx:  No masses or lesions in vallecula, piriform
sinuses, or post-cricoid area; no erythema; no pooling of
secretions - mildly narrowed hypopharynx and oropharynx in the
A-P diameter
Larynx:   Epiglottis non-edematous or erythematous; True vocal
cords symmetric with normal movement bilaterally; Arytenoids
without erythema, normal movement of vocal processes; no mass
lesions

DISCHARGE PHYSICAL EXAM:  
VITALS: T98.4 BP 120/77 HR 62 RR 14 O2 sat 97 on RA. 

General: in NAD
HEENT: NC/AT. dark discoloration in soft tissue under tongue in 
sublingual region without evidence of active bleeding, no 
significant swelling.
Neck: no cervical LAD
Lungs: LCTAB, no wheezes, rales, rhonchi  .
CV: RRR, mechanical heart sounds in all heart fields.
GI: abdomen soft, NT, ND.
Ext: no ___ edema, no evidence of ecchymoses.
Neuro: moving all extremities spontaneously.
 
Pertinent Results:
Pertinent Labs
--------------------

___ 06:00AM BLOOD WBC-7.1 RBC-5.05 Hgb-17.5 Hct-49.9 
MCV-99* MCH-34.7* MCHC-35.1 RDW-13.0 RDWSD-46.9* Plt ___
___ 06:35PM BLOOD WBC-4.7 RBC-4.56* Hgb-15.6 Hct-44.3 
MCV-97 MCH-34.2* MCHC-35.2 RDW-12.4 RDWSD-44.5 Plt ___
___ 04:07AM BLOOD WBC-3.9* RBC-4.24* Hgb-14.3 Hct-41.7 
MCV-98 MCH-33.7* MCHC-34.3 RDW-12.4 RDWSD-44.8 Plt ___
___ 07:00AM BLOOD WBC-4.5 RBC-3.88* Hgb-13.4* Hct-39.5* 
MCV-102* MCH-34.5* MCHC-33.9 RDW-12.7 RDWSD-47.1* Plt ___
___ 05:35AM BLOOD WBC-3.5* RBC-3.87* Hgb-13.5* Hct-40.1 
MCV-104* MCH-34.9* MCHC-33.7 RDW-12.9 RDWSD-48.3* Plt ___
___ 07:38AM BLOOD ___ PTT-107.0* ___
___ 01:09PM BLOOD ___ PTT-42.7* ___
___ 06:15PM BLOOD ___ PTT-32.2 ___
___ 05:35AM BLOOD ___ PTT-83.7* ___
___ 06:00AM BLOOD Glucose-103* UreaN-7 Creat-0.8 Na-135 
K-6.3* Cl-100 HCO3-19* AnGap-16
___ 04:07AM BLOOD Glucose-129* UreaN-13 Creat-0.7 Na-138 
K-5.0 Cl-103 HCO3-20* AnGap-15
___ 07:00AM BLOOD Glucose-106* UreaN-15 Creat-0.9 Na-143 
K-4.4 Cl-105 HCO3-29 AnGap-9*

PERTINENT IMAGING
CT Neck ___
IMPRESSION: 
1. Suboptimal evaluation of the floor of the mouth secondary to
extensive streak artifact emanating from dental amalgam. 
2. Within these limitations, small ill-defined hypodense area in
the left submandibular region, measuring 6 mm concerning for
edema, with differential consideration of phlegmonous change. 
3. Within limits of study, no definite abscess identified. 
 
Brief Hospital Course:
BRIEF HOSPITAL COURSE

Mr. ___ is a ___ h/o marfanoid features and MVR 
replacement ___ on warfarin p/w several days of increasing 
swelling at the base of his tongue, found to have 
supratherapeutic INR with concern for submandibular bleed.

Two days prior to presentation, ___, he noted a sore throat 
and some swelling in his lymph nodes, and then the next day some 
swelling in his mouth that made it hard for him to talk. He 
noted swelling and dark discoloration developing at the base of 
the tongue. Also developed tongue swelling, and fullness in his 
neck and jaw. He endorsed dysphagia and dysarthria ___ tongue 
swelling, but denied dyspnea or SOB. He came to the ED early 
___ for evaluation. 

On arrival to the ED, his INR was found to be supratherapeutic 
to 11.1 (therapeutic range 2.5-3.5). No e/o infection or trauma. 
Attributes poor control to dietary indiscretion and EtOH. 
Typically drinks 1 bottle wine/day but was drinking more in 
celebratory settings over past ___emonstrated a 
6mm hypodensity in the left submandibular area. Given 
dexamethasone x1 in ED. He was admitted to SICU for airway watch 
in the setting of submandibular bleed secondary to 
supratherapeutic INR. 

Swelling improved considerably in SICU. INR decreased to 0.9. No 
evidence of additional bleeding. No SOB. He was transferred to 
medicine on ___. On the floor, the swelling continued to 
improve and by ___ the day of discharge was nearly entirely 
resolved. He was bridged back on to 7.5mg warfarin daily using 
initially heparin from ___ and then Lovenox from ___ to 
ongoing.

#submandibular hematoma, likely in setting of supratherapeutic 
INR. Warfarin reversed with ___ and vitamin K. Restarted 
warfarin on ___ at 7.5mg daily with initially heparin and then 
lovenox bridge. Swelling resolved by the time of discharge, with 
no evidence of active bleeding. INR was 1.0 on ___ and 1.1 on 
___ day of discharge. 

#history of MVR, on warfarin for mechanical valve. Warfarin 
reversed, then restarted with heparin then lovenox bridge as 
above. Patient was counselled about lifestyle/diet in setting of 
warfarin use. Aspirin was held in the setting of active bleed. 

#EtOH use. Patient reported more recent EtOH use, as well as 
history of ICU stay of withdrawal (though per his report does 
not seem that history of DTs.) No signs of DT or withdrawal in 
the SICU. Was monitored on a ___ protocol while on the medicine 
floor, where he also had no signs of DT or withdrawal. He was 
given folate, thiamine, and multivitamin. He was counselled on 
EtOH cessation. He felt motivated by this bleeding incident to 
get his alcohol abuse under control, and expressed interest in 
PO naltrexone(Vivitrol). He was given one dose of PO before 
discharge and tolerated it well. He has an appointment with Dr. 
___ from addiction psychiatry to follow up as outpatient. 


#HTN
> continued home meds:
Metoprolol Tartrate 25 mg PO/NG BID 
Losartan Potassium 25 mg PO/NG DAILY

#Buproprion
> continued home BuPROPion (Sustained Release) 150 mg PO BID 

TRANSITIONAL ISSUES
=========================
New medications: 
- Naltrexone 50 mg PO daily
- Lovenox 80 mg SC Q12H (resumed, previous home medication for 
bridging)

HELD MEDICATIONS
- ___ 81 mg
(held until discussed with PCP)

[] ___ 81 mg held in setting of active hematoma while inpatient; 
please discuss when it is safe to resume this medication
[] please continue to monitor patient's alcohol cravings on 
Naltrexone PO
[] please ensure patient keeps psychiatry f/u with Dr. ___
[] please ensure he gets INR check on ___, with Coumadin 
Dosing to be adjusted by ___ (Dr. ___

discharge anticoagulation plan:
- dose of lovenox at 2:15 AM on ___ (after receiving dose on 
2:15 ___ of ___
- continue warfarin 7.5 mg on ___ (given dose in the 
hospital) and 7.5 mg on ___.
- INR check ___ and wait for instructions from the ___ 
___ on how much warfarin to take.

Mr. ___ is clinically stable for discharge today. The total 
time spent today on discharge planning, counseling and 
coordination of care was greater than 30 minutes.
 
Medications on Admission:
The Preadmission Medication list is accurate and complete.
1. Warfarin 7.5 mg PO 6X/WEEK (___) 
2. Aspirin 81 mg PO DAILY 
3. Losartan Potassium 50 mg PO DAILY 
4. Metoprolol Tartrate 25 mg PO BID 
5. Cyanocobalamin Dose is Unknown  PO DAILY 
6. BuPROPion (Sustained Release) 150 mg PO BID 
7. Rosuvastatin Calcium 20 mg PO QPM 
8. Multivitamins 1 TAB PO DAILY 
9. Warfarin 5 mg PO 1X/WEEK (FR) 
10. Enoxaparin Sodium 80 mg SC Q12H 
Start: Today - ___, First Dose: Next Routine Administration 
Time 

 
Discharge Medications:
1.  Naltrexone 50 mg PO DAILY 
RX *naltrexone 50 mg 1 tablet(s) by mouth daily Disp #*30 Tablet 
Refills:*0 
2.  Warfarin 7.5 mg PO DAILY16 
please take 7.5 mg of warfarin on ___, then get your INR 
checked on ___.   
3.  BuPROPion (Sustained Release) 150 mg PO BID  
4.  Cyanocobalamin 50 mcg PO DAILY  
5.  Enoxaparin Sodium 80 mg SC Q12H 
Start: Today - ___, First Dose: Next Routine Administration 
Time  
6.  Losartan Potassium 50 mg PO DAILY  
7.  Metoprolol Tartrate 25 mg PO BID  
8.  Multivitamins 1 TAB PO DAILY  
9.  Rosuvastatin Calcium 20 mg PO QPM  
10. HELD- Aspirin 81 mg PO DAILY  This medication was held. Do 
not restart Aspirin until ___ discuss it with your PCP

 
___:
Home
 
Discharge Diagnosis:
ACUTE ISSUES
=============
submandibular hematoma
alcohol abuse

 
Discharge Condition:
Mental Status: Clear and coherent.
Level of Consciousness: Alert and interactive.
Activity Status: Ambulatory - Independent.

 
Discharge Instructions:
Dear Dr. ___, 

___ were admitted to the hospital with swelling of the base of 
your tongue. Imaging (CT) showed a submandibular hematoma. ___ 
were found to have an INR higher than the therapeutic range, 
indicating that your blood had become very thin. This was likely 
due to recent heavy alcohol use increasing the effect of your 
warfarin. 

We treated ___ by reversing the effect of the warfarin 
(Coumadin) with Vitamin K and fresh frozen plasma. To bridge ___ 
back on to warfarin, we used a heparin drip and then Lovenox. 
___ should continue to take the Lovenox at home until told to 
stop by the ___ clinic.

Anticoagulation plan: 
- please take dose of lovenox at 2:15 AM on ___ (after receiving 
dose on 2:15 ___ of ___
- ___ can continue to make these doses slightly earlier to get 
them back on a normal schedule over time
- please continue to take warfarin 7.5 mg on ___ (we will 
give ___ your dose in the hospital) and 7.5 mg on ___.
- please get your INR checked on ___ and wait for 
instructions from the ___ on how much warfarin to 
take.

It is very important to treat your alcohol abuse. ___ told us 
that ___ were interested in Vivitrol (naltrexone), and we 
commend ___ on taking this step forward. ___ received one dose 
before discharge. 

___ should continue to take the Vivitrol at home: *** 50mg every 
day. 

Please keep the appointments that we made for ___ below, 
especially the appointment with Dr. ___.

Sincerely,
Your ___ Medicine Team

 
Followup Instructions:
___